Drugs / SSS06
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06854276 | Mar 2025 → Dec 2027 expected | aregenerative anemia | Shenyang Sunshine Pharmaceutical Co., LTD. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SSS06 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06854276 ↗ |
| Modality | Protein / enzyme biologic | “SSS06 is a highly glycosylated, long-acting recombinant protein product” NCT06854276 ↗ |